TORL BioTherapeutics
Culver City, CA
TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.
torlbio.comCompany Details
Founded
- 2018
Employees
- Between 10 - 100 employees
Raised
- $412,000,000
Headquarters Location
- Culver City, CA
Public
- No
Acquired
- No
CEO
Mark Alles
Founders
- Dennis SlamonNeil O'Brien
Company Collections
These are collections TORL BioTherapeutics is a part of. Click on the collection name to view similar companies.
TORL BioTherapeutics' Industries
TORL BioTherapeutics Headquarters Location
Culver City, CA 90232
Total Amount Raised: $412,000,000
TORL BioTherapeutics Funding Rounds
Series C
$96,000,000
Series C
$96,000,000
Series B
$158,000,000
Series B
$158,000,000
Series B Investors
Deep Track CapitalRA Capital ManagementBristol-Myers Squibb CompanyVertex Ventures HCAvidity Partners ManagementBlue Owl CapitalMoore Strategic VenturesGoldman SachsUniversity of California Office of the PresidentPerceptive AdvisorsXontogenyUC InvestmentsGianna Hoffman-LucaSeries B
$158,000,000
Series B
$158,000,000
Series B Investors
Goldman Sachs Asset ManagementCowen Healthcare InvestmentsVertex Ventures HCMoore Strategic VenturesBristol-Myers Squibb CompanyAlexandria Real Estate EquitiesDeep Track CapitalOCVUC InvestmentsPerceptive AdvisorsVest Coast Capital
Funding info provided by Diffbot.
TORL BioTherapeutics Reviews
0 out of 5 stars
Based on 0 reviews
Review data
Share your thoughts
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on TORL BioTherapeutics.